Compare · ATHE vs ONTX
ATHE vs ONTX
Side-by-side comparison of Alterity Therapeutics Limited (ATHE) and Onconova Therapeutics Inc. (ONTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATHE and ONTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ATHE is the larger of the two at $60.2M, about 1.7x ONTX ($36.3M).
- ATHE has hit the wire 5 times in the past 4 weeks while ONTX has been quiet.
- ATHE has more recent analyst coverage (3 ratings vs 1 for ONTX).
- Company
- Alterity Therapeutics Limited
- Onconova Therapeutics Inc.
- Price
- $3.91-2.49%
- $1.01+4.12%
- Market cap
- $60.2M
- $36.3M
- 1M return
- -14.44%
- -
- 1Y return
- -18.20%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2013
- News (4w)
- 5
- 0
- Recent ratings
- 3
- 1
Alterity Therapeutics Limited
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.
Onconova Therapeutics Inc.
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Latest ATHE
- SEC Form 6-K filed by Alterity Therapeutics Limited
- SEC Form 6-K filed by Alterity Therapeutics Limited
- SEC Form 6-K filed by Alterity Therapeutics Limited
- Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
- SEC Form 6-K filed by Alterity Therapeutics Limited
- SEC Form 6-K filed by Alterity Therapeutics Limited
- Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
- SEC Form 6-K filed by Alterity Therapeutics Limited
- Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
- SEC Form 6-K filed by Alterity Therapeutics Limited
Latest ONTX
- SEC Form 10-K/A filed by Onconova Therapeutics Inc. (Amendment)
- SEC Form D filed by Onconova Therapeutics Inc.
- SEC Form DEFA14A filed by Onconova Therapeutics Inc.
- Onconova Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- New insider Orbimed Advisors Llc claimed ownership of 1,045,261 shares (SEC Form 3) (Amendment)
- New insider Tpav, Llc claimed ownership of 1,222,738 shares (SEC Form 3) (Amendment)
- SEC Form SC 13D filed by Onconova Therapeutics Inc.
- Redfield Robert was granted 97,500 shares (SEC Form 4)
- Pauza Charles David was granted 97,500 shares (SEC Form 4)
- Cautreels Werner was granted 200,000 shares (SEC Form 4)